filed 8-18-03

Form PTO-1449 Modified List of Patents and Publications Cited by Application (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. ISPH-0764	Serial No. not yet assigned
	Applicant C. Frank Bennett *et al.*	
	Filing Date herewith	Group 1635

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	AA	Abe *et al., Group II phospholipase A2 is increased in peritoneal and pleural effusions in patients with various types of cancer, Int. J. Cancer,* 1997, 74:245-250.
	AB	Barbour *et al., Antisense inhibition of group II phospholipase A2 expression blocks the production of prostaglandin E2 by P388D1 cells, J. Biol. Chem.,* 1993, 268:21875-21882.
	AC	Bennett et al., *Sequence specific inhibition of human type II phospholipase A2 enzyme activity by phosphorothioate oligonucleotides, Nucleic Acid Res.,* 1994, 22, 3202-3209.
	AD	Bidgood *et al., Type IIA secretory phospholipase A2 up-regulates cyclooxygenase-2 and amplifies cytokine-mediated prostaglandin production in human rheumatoid synoviocytes, J. Immunol.,* 2000, 165:2790-2797.
	AE	Bryant *et al., 1,3-Dioxane-4,6-dione-5-carboxamide-based inhibitors of human group IIA phospholipase A: X-ray structure of the complex and interfacial selection of inhibitors from a structural library, Bioorg. Med. Chem. Lett.,* 1999, 9:1097-1102.
	AF	Chilton *et al., Antigen-induced generation of lyso-phospholipids in human airways, J. Exp. Med.,* 1996, 183:2235-2245.
	AG	Cupillard *et al., Cloning, chromosomal mapping, and expression of a novel human secretory phospholipase A2, J. Biol. Chem.,* 1997, 272:15745-15752.
	AH	Dennis, *Diversity of group types, regulation, and function of phospholipase A2, J. Biol. Chem.,* 1994, 269:13057-13060.
	AI	Dennis, *The growing phospholipase A2 superfamily of signal transduction enzymes, Trends Biochem. Sci.,* 1997, 22:1-2.
	AJ	Dorsam *et al., Diphenyleneiodium chloride blocks inflammatory cytokine-induced up-regulation of group IIA phospholipase A(2) in rat mesangial cells, J. Pharmacol. Exp. Ther.,* 2000, 292:271-279.

EXAMINER	DATE CONSIDERED
	5-2-06

Form PTO-1449 Modified List of Patents and Publications Cited by Application (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. ISPH-0764	Serial No. not yet assigned
	Applicant C. Frank Bennett *et al.*	
	Filing Date herewith	Group 1635

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	AK	Furue *et al., Crucial role of group IIA phospholipase A(2) in oleic acid-induced acute lung injury in rabbits, Am. J. Respir. Crit. Care Med.*, 1999, *160*:1292-1302.
	AL	Ivandic *et al., Role of group II secretory phospholipase A2 in atherosclerosis: 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIa phospholipase A2, Arterioscler. Thromb. Vasc. Biol.*, 1999, *19*:1284-1290.
	AM	Jamal *et al., Increased expression of human type IIa secretory phospholipase A2 antigen in arthritic synovium, Ann. Rheum. Dis.*, 1998, *57*:550-558.
	AN	Kano *et al., Effects of long-term ursodeoxycholate administration on expression levels of secretory low-molecular-weight phospholipases A2 and mucin genes in gallbladders and biliary composition in patients with multiple cholesterol stones, Hepatology*, 1998, *28*:302-313.
	AO	Koike *et al., Group IIA phospholipase A2 mediates lung injury in intstinal ischemia-reperfusion, Ann. Surg.*, 2000, *232*:90-97.
	AP	Koyama *et al., Elevations of group II phospholipase A2 concentrations in serum and amniotic fluid in association with preterm labor, Am.J. Obstet. Gynecol.*, 2000, *183*:1537-1543.
	AQ	Kudo *et al., Mammalian non-pancreatic phospholipases A2, Biochim. Biophys. Acta*, 1993, *1170*:217-231.
	AR	Lilja *et al., Presence of group IIa secretory phospholipase A2 in mast cells and macrophages in normal human ileal submucosa and in Crohn's disease, Clin. Chem. Lab Med.*, 2000, *38*:1231-1236.
	AS	Lin *et al., Secretory phospholipase A2 as an index of disease activity in rheumatoid arthritis. Prospective double blind study of 212 patients, J. Rheumatol.*, 1996, *23*:1162-1166.
	AT	Minami *et al., Elevation of phospholipase A2 protein in sera of patients with Crohn's disease and ulcerative colitis, Am. J. Gastroenterol.*, 1993, *88*:1076-1080.

EXAMINER	DATE CONSIDERED 5-2-06

Form PTO-1449 Modified List of Patents and Publications Cited by Application (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. ISPH-0764	Serial No. not yet assigned
	Applicant C. Frank Bennett *et al.*	
	Filing Date herewith	Group 1635

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	AU	Minami *et al.*, *Increased group II phospholipase A2 in colonic mucosa of patients with Crohn's disease and ulcerative colitis*, Gut, 1994, 35:1593-1598.
	AV	Nevalainen, *Serum phospholipases A2 in inflammatory diseases*, Clin. Chem., 1993, 39:2453-2459.
	AW	Pruzanski *et al.*, *Circulating group II phospholipase A2 activity and antilipocortin antibodies in systemic lupus erythematosus. Correlative study with disease activity*, J. Rheumatol., 1994, 21:252-257.
	AX	Pruzanski *et al.*, *Lipoproteins are substrates for human secretory group IIA phospholipase A2: preferential hydrolysis of acute phase HDL*, J. Lipid Res., 1998, 39:2150-2160.
	AY	Shoda *et al.*, *Secretory low-molecular-weight phospholipases A2 and their specific receptor in bile ducts of patients with intrahepatic calculi: factors of chronic proliferative cholangitis*, Hepatology, 1999, 29:1026-1036.
	AZ	Snyder *et al.*, *Pharmacology of LY315920/S-5920, [[3-(aminooxoacetyl)-2-ethyl-1- (phenylmethyl)-1H-indol-4-yl]oxy] acetate, a potent and selective secretory phospholipase A2 inhibitor: A new class of anti-inflammatory drugs, SPI*, J. Pharmacol. Exp. Ther., 1999, 288:1117-1124.
	BA	Vadas *et al.*, *Extracellular phospholipase A2 expression and inflammation: the relationship with associated disease states*, J. Lipid Mediat., 1993, 8:1-30.
	BB	Wada *et al.*, *Systemic autoimmune nephritogenic components induce CSF-1 and TNF-alpha in MRL kidneys*, Kidney Int., 1997, 52:934-941.
	BC	Weinrauch *et al.*, *Mobilization of potent plasma bactericidal activity during systemic bacterial challenge. Role of group IIA phospholipase A2*, J. Clin. Invest., 1998, 102:633-638.

EXAMINER	DATE CONSIDERED 5-2-06

Form PTO-1449 Modified List of Patents and Publications Cited by Application (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. I3PH-0764	Serial No. not yet assigned
	Applicant C. Frank Bennett *et al.*	
	Filing Date herewith	Group 1635

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

BD		Yokota *et al.*, *Suppression of murine endotoxic shock by sPLA2 inhibitor, indoxam, through group IIA sPLA2-independent mechanisms, Biochim. Biophys. Acta*, 1999, *1438*:213-222.

EXAMINER	DATE CONSIDERED
	5-2-06

Form PTO-1449 Modified List of Patents and Publications Cited by Application (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. ISPH-0764	Serial No.
	Applicant C. Frank Bennett et al.	
	Filing Date	Group 1635

U.S. PATENT DOCUMENTS

Examiner's Initial		Document No.	Date	Name	Class	Subclass
JZ	AA	5,019,508	5/28/1991	Johnson *et al.*	434	198
	AB					
	AC					
	AD					
	AE					
	AF					
	AG					
	AH					
	AI					
	AJ					
	AK					
	AL					
	AM					
	AN					

FOREIGN PATENT DOCUMENTS

Examiner's Initial		Document No.	Date	Country	Translation YES	Translation NO
JZ	AO	WO 91/16901	11/14/1991	PCT		
	AP					
	AQ					
	AR					
	AS					
	AT					
	AU					
	AV					
	AW					
	AX					

EXAMINER JZ DATE CONSIDERED 5-2-06

Form PTO-1449 Modified List of Patents and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce	Docket No. **ISPH-0764**	Serial No. **Not yet assigned**
	Applicant **Bennett and Wyatt**	
	Filing Date **Herewith**	Group 1635 ~~Not yet assigned~~

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

JB	BA	Milner et al., "Selecting effective antisense reagents on combinatorial oligonucleotide arrays", Nature Biotechnology 1997 15:537-541

EXAMINER	DATE CONSIDERED
	5-2-06

Form PTO-1449 Modified List of Patents and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. ISPH-0764	Serial No. Not yet assigned
	Applicant Bennett and Wyatt	
	Filing Date Herewith	Group 1635 ~~Not yet assigned~~

U. S. PATENT DOCUMENTS

Examiner		Document	Date	Name	Class	Subclass
DZ	CA	5,877,309	3-2-99	McKay et al.	536	24.5

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation YES	NO

EXAMINER DZ	DATE CONSIDERED 5-2-06